Physician profile
Zanetta Batts
NPI 1811525322
$2,127.16
in general payments reported to CMS, 2019-2025
22 companies · $784 in 2025
The $784 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $427 · 2024: $916 · 2025: $784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,127.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $509.43 | 2023-2025 | Vraylar |
| Novo Nordisk INC | $376.32 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $196.75 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $146.72 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $135.99 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $130.67 | 2023-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.52 | 2023-2025 | Jardiance |
| Glaxosmithkline, LLC. | $108.29 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Exact Sciences Corporation | $57.06 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $51.04 | 2025 | Spravato |
| Sumitomo Pharma America, INC. | $46.13 | 2024 | Gemtesa |
| Gilead Sciences, INC. | $37.80 | 2025 | Epclusa |
| Dynavax Technologies Corporation | $34.53 | 2023-2024 | Heplisav-B |
| Bayer Healthcare Pharmaceuticals INC. | $29.97 | 2025 | |
| Boston Scientific Corporation | $29.09 | 2025 | Wavewriter Alpha Prime 16 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $20.82 | 2024 | Prolastin-C Liquid |
| Sanofi-Aventis U.S. LLC | $19.60 | 2023 | |
| Esperion Therapeutics, INC. | $17.69 | 2023 | Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.07 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $13.75 | 2024 | Gardasil, Capvaxive, Gardasil 9 |
| Eisai INC. | $13.50 | 2024 | |
| Corium, LLC | $12.42 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zanetta Batts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.